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The molecular structure of the DNA A-tract dodecamer d(CGCAAATTTGCG) complexed with 
the drug Hoechst 33258 has been determined by X-ray diffraction analysis. The Hoechst molecule 
binds in the DNA minor groove covering the sequence AATTT of the central A-tract, with the 
piperazine group close to one of the GC regions. The drug molecule makes two three-centered 
hydrogen bonds from the nitrogen atoms of the benzimidazole rings to the N3 and 0 2  atoms of the 
DNA bases. Although a high propeller twist is observed in the A-tract, only one unsymmetrical 
three-centered hydrogen bond is present in the DNA major groove. The structure is compared with 
other minor-groove-binding drug complexes and the influence of these drugs on DNA A-tracts is 
discussed. 
Hoechst 33258 [chemical name: 2’-(4-hydroxyphenyl)- 
5-(4-methyl-l-piperazinyl)-2,5’-bi-benzimidazole], netropsin 
and distamycin are DNA minor-groove-binding drugs with 
common structural features : (a) they are molecules contain- 
ing planar segments due to the presence of aromatics groups ; 
(b) they are non-symmetrical molecules ; (c) they are posi- 
tively charged and (d) they have an arc-like shape which 
allows them to follow the minor groove when interacting 
with the DNA double helix. Furthermore, these molecules 
have affinity for A+T-rich sequences over G+ C-containing 
sequences mostly due to steric factors (Burckhardt et al., 
1985). The presence of the N2 amino group in guanine pre- 
vents the binding of the drug in the DNA minor groove 
(Kopka et al., 1985), although Hoechst 33258 tolerates G-C 
pairs at the edge of the binding site (Harshman and Dervan, 
1985 ; Portugal and Waring, 1988). 
Hoechst 33258 is a synthetic N-methyl piperazine deriva- 
tive with two benzimidazole groups and one phenyl group 
(Fig. 1). It has antihelminthic activity (Lammler et al., 1971) 
and is commonly used as a fluorescent cytological stain for 
DNA (Hilwig and Gropp, 1972; Holmquist, 1975). Hoechst 
33258 binds preferentially to A+T-rich regions as deter- 
mined by fluorescence (Latt and Wohlleb, 1975 ; Holmquist, 
1975), footprinting (Harshman and Dervan, 1985) and ‘”1- 
DNA cleavage (Martin and Holmes, 1983; Murray and Mar- 
tin, 1988). 
There are several X-ray diffraction studies of this drug 
complexed with two different dodecamers. The complex 
Hoechst 33258-d(CGCGAATTCGCG) has been reported by 
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Fig. 1. Atomic numbering scheme of the Hoechst 33258 molecule. 
The drug has four structural groups: a phenyl ring (Ph), two benzim- 
idazole rings (Bzl and Bz2) and a piperazine ring (Pip). The torsion 
angles between the four structural groups are indicated with arrows. 
The N1 and N3 atoms interact with the bases at the floor of the 
DNA minor groove. 
Pjura et al. (1987), Teng et al. (1988) and Quintana et al. 
(1991). The different analyses show some discrepancies in 
the positioning of the drug along the minor groove which 
might be due to different crystallization conditions or dif- 
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ferent interpretations of the electron density maps. The com- 
plex of Hoechst 33258 with the alternating sequence 
d(CGCGATATCGCG) has been studied by Carrondo et al. 
(1989). Recently Sriram et al. (1992) have reported the com- 
plex with the dodecamer d(CGC[e'G]AATTCGCG), where 
e6G stands for 06-ethylguanine. In all these complexes the 
DNA sequence has four A . T base pairs which is approxi- 
mately the length of the Hoechst dye. However the drug mol- 
ecule does not bind in the same position when the central 
sequence is AATT or ATAT. A sequence-dependent specific- 
ity seems to drive the drug binding. 
In this paper we report the structural analysis of the com- 
plex of Hoechst 33258 with the DNA dodecamer d(CGCAA- 
ATTTGCG). In this dodecamer the central A . T region is 
longer than the length of the drug and therefore several bind- 
ing areas are possible along the A-tract. In the complex struc- 
ture of the same dodecamer with the drugs distamycin and 
netropsin we have observed a single binding site (or at least 
a major site) rather than a disorder between several positions 
along the groove (Coll et al., 1987; Tabernero et al., 1993). 
We wanted to test, with a different drug, if this is a gene- 
ral characteristic of minor-groove-binders. In addition, the 
complex reported here is compared with other Hoechst 
33258-DNA complexes and the influence of drug binding on 
the central A-tract is analyzed. 
EXPERIMENTAL PROCEDURES 
The DNA dodecamer d(CGCAAATTTGCG) was synthe- 
sized and purified as described (van der Marel et al., 1981). 
Suitable crystals of the complex were grown by vapour diffu- 
sion at room temperature from sittings drops containing 
1 mM DNA dodecamer, re-purified from previous crystalli- 
zation drops by HPLC, 1 mM Hoechst-33258, 19.5% 2- 
methyl-2,4-pentanediol, 1 mM sodium cacodylate pH = 7 
and 0.7 mM spermine, equilibrating against a reservoir of 
50% 2-methyl-2,4-pentanediol. 
A crystal of approximate dimensions 0.2X0.35 XO.5 mm 
was mounted in a glass capillary with a droplet of mother 
liquor. The crystal was orthorhombic, space group P2,2,2,, 
with unit cell dimensions a = 2.55 nm, b = 4.15 nm and 
c = 6.53 nm, thus being isomorphous with the original 
d(CGCGAATTCGCG) dodecamer (Wing et al., 1980). 
Three-dimensional diffraction data were collected up to 
0.24-nm resolution, at room temperature, using a Mar Re- 
search imaging plate area detector installed on an Elliot 
GX21 rotating anode X-ray generator. 
Images were taken in 5" rotation steps with the detector 
set at 110mm distance. The data were processed with the 
MOSFLM package (Leslie, 1991). A total of 9285 reflections 
were measured of which 2291 were considered unique above 
the 20(F0) level, and the Rmcrge was 6.1%. Table 1 shows the 
completeness of the data set. 
The DNA coordinates from the crystal structure dista- 
mycin-d(CGCAAATTTGCG) (Coll et al., 1987) were used 
as a starting model. This model was first refined as a rigid 
body using the XPLOR package (Briinger, 1992) and a reso- 
lution range of 1.0-0.4 nm whereby the R-factor dropped 
from 33.3% to 31.2%. A combined X-ray and energy mini- 
mization refinement followed with XPLOR, increasing the 
resolution progressively up to 0.24 nm R here the R-factor 
was 31.0%. Fourier maps with coefficients 2F0-F, and Fo- 
F, were calculated at this point. These maps clearly showed 
a strong residual electron density in the DNA minor groove 
Table 1. Completeness of data for the Hoechst 33258-d(CGCAA- 
ATTTGCG) complex [Fn > 20 (Fn)l. 
















corresponding to the drug molecule. The Hoechst molecule 
was fitted into the electron density using the computer graph- 
ics program TOM-FRODO (Cambillau and Horjales, 1987 ; 
Jones, 1978). Hoechst 33258 is a non-symmetrical molecule 
and consequently the existence of two possible orientations 
in the crystal was considered. Only in one orientation could 
the drug be fitted completely in the electron density with the 
bulkier piperazine ring positioned at one end of the A-tract. 
The structure was further refined and solvent molecules 
were added. The location of the drug molecule was con- 
firmed by calculating an omit map after a refinement run 
excluding the drug atoms (Fig. 2). The final R-factor is 20% 
for 2253 reflections between 1.0-0.24 nm. In the final struc- 
ture the root-mean-square deviation from target values is 
0.0019 nm for bond lengths and 3.71" for bond angles. The 
atomic coordinates have been deposited with the Brookhaven 
Protein Data Bank. 
Empirical force-field calculations were performed for de- 
termining H-bond interactions using a dielectric constant E = 
lr .  All parameters were taken from the Amber data base 
(Weiner et al., 1986). Angles between mean planes of the 
drug were calculated with the program QUEST written by G. 
Quigley. DNA parameters were calculated with the program 
NEWHEL92 written by R. Dickerson. 
RESULTS AND DISCUSSION 
Drug-DNA interactions 
Figs 2 and 3 show the final structure of the complex with 
the drug molecule inserted into the minor groove of the DNA 
double helix. The drug molecule covers approximately five 
of the six central A . T base pairs from AS . T20 to T9 . 
A16. It is therefore displaced to one end of the A-tract with 
the piperazine ring positioned between the T9 . A16 base 
pair and G10 . C15 base pair. In this area, the minor groove 
is less narrow than in the midst of the A-tract and the non- 
planar piperazine moiety seems to fit more easily in the 
groove. Footprinting experiments, showing that Hoechst 
33258 binds either to all-A . T segments or to A . T stretches 
with a G . C base pair at one edge, are in agreement with our 
results (Harshman and Dervan, 1985; Portugal and Waring, 
1988). 
The N1 and N3 atoms of the benzimidazole groups of the 
drug (Fig. 1) interact with the bases at the floor of the minor 
groove by two three-centered hydrogen bonds (Fig. 4 and 
Table 2). Nitrogen N1 of the drug molecule interacts with 
oxygen 0 2  of thymine T7 and oxygen 0 2  of thymine T19, 
at the central ApT step. Nitrogen N3 is hydrogen bonded to 
Fig. 2. Stereo view of an omit difference Fourier map calculated 
without the Hoechst 33258 atoms and after a few cycles of refine- 
ment. The drug molecule is shown fitted in the residual electron 
density. No disorder in its position along the groove is observed. 
Fig. 3. Skeletal representation of the d(CGCAAATTTGCG) do- 
decamer with the Hoechst 33258 dye inserted into the minor 
groove and represented as van der Waals spheres. The drug mole- 
cule is displaced from the center of the DNA sequence. Drawing 
generated with TURBO (Roussel & Cambillau, 1991). 
the N3 atom of adenine A38 and the 0 2  atom of thymine 
T8. The 01 hydroxyl atom of the phenyl group at one end 
of the drug interacts weakly (0.36 nm) with the 04’ atom 
723 
Table 2. Drug-DNA hydrogen bond distance in the Hoechst 
33258-d(CGCAAATTTGCG) complex. 








04’ (T21) 0.36 
0 2  (T19) 0.26 
0 2  (T7) 0.30 
0 2  (T8) 0.30 
N3 (A18) 0.33 
03’ (C24”) 0.32 
a Base from a symmetry-related molecule. 
from the deoxyribose of thymine T21. In the present crystal 
structure, as occurs in the other isomorphous dodecamer 
structures, the DNA molecules pack along the c axis with 
a two-base-pair overlap. The sugar-phosphate backbones of 
symmetry-related molecules are inserted at both ends of the 
minor groove. The terminal 03’ hydroxyl atom of one of 
these neighbouring molecules interacts with the N6 atom of 
the piperazine group of the drug. 
Besides the hydrogen bonding interactions, the drug- 
DNA complex is also stabilized by van der Waals interac- 
tions between the sugar-phosphate backbone at the side walls 
of the groove and the TC electron density clouds of the aro- 
matic rings (i.e. phenol group, benzimidazole groups), as oc- 
curs in other minor-groove-binding drug complexes. As men- 
tioned above, the drug molecule is clearly displaced from the 
center of the A-tract leaving the A4 . T21 pair uncovered. 
This is in contrast with the complex structures reported with 
the DNA dodecamer d(CGCGAATTCGCG) (Teng et al., 
1988; Quintana et al., 1991), where the Hoechst dye occupies 
a more central position (Fig. 4B and C). The differences are 
obviously related to the longer A-tract present in our struc- 
ture. However, because the A-tract is longer than the length 
of the drug, a disorder in its position along the tract could be 
expected. This is not the case or, at least, there is a major 
position and orientation of the drug molecule in the groove. 
The same was observed in the complex of the present six- 
base-pair A-tract dodecamer with the drugs distamycin (Coll 
et al., 1987) and netropsin (Tabernero et al., 1993). We note 
that, even though the DNA sequence is palindromic, a true 
crystallographic twofold axis is not present in this crystal 
form. The two sides of the dodecamer are different in their 
detailed conformations and have different packing environ- 
ments. As in the distamycin and netropsin complexes, the 
major position and orientation of the drug must be the one 
with lower energy, where more drug-DNA interactions are 
satisfied and less repulsive contacts occur. As depicted in 
Fig. 4A and Table 2, all hydrogen bond donors of the drug 
interact with DNA atoms, including two three-centered hy- 
drogen bonds from N1 and N3. This kind of bifurcated hy- 
drogen bonds imply that more H-bond acceptors in the DNA 
are satisfied than with single hydrogen bonds. 
In the complex of Hoechst 33258 with the alternating 
sequence d(CGCGATATCGCG) (Carrondo et a]., 1989) the 
drug molecule presents an opposite orientation with respect 
to the one reported here. The piperazine group is located in 
that structure covering the G4 . C21 base pair. The sugar 
moiety seems to fit better in that position where the minor 
groove is also less narrow. In the d(CGCAAATTTGCG) 









Fig. 4. Stereo drawing of the central region of different DNA dodecamers complexed with minor-groove-binding drugs. Only the 
DNA bases (open bonds) and the drug molecules (solid bonds) are shown. Hydrogen bonds between the drug and the DNA are indicated 
as thin lines. (A) Hoechst 33258-d(CGCAAATTTGCG) complex (this work) ; (B) Hoechst 33258-d(CGCGAATTCGCG) complex (Teng 
et al., 1988); (C) Hoechst 33258-d(CGCGAATTCGCG) complex (Quintana et al., 1991); (D) netropsin-d(CGCAAATTTGCG) complex 
(Tabernero et al., 1993); (E) dystamicin-D(CGCAAATTTGCG) complex (Coll et al., 1987) ; (F) berenyl-d(CGCAAATTTGCG) complex 
(Brown et al., 1992). 
base pair but it is located where the minor groove starts to 
open up, four base pairs from one end of the dodecamer. A 
polar projection of the complex is shown in Fig. 5.  The minor 
groove width (represented as 04'-04' distances across the 
groove less their van der Waals radii) is about 0.45 nm in 
most of the A-tract segment (i.e. when the A and T residues 
face in opposite strands). The groove opens up over 0.5 nm 
at the G10/A18 and Cll/A17 level, the precise location of 
the piperazine ring. Note that although the A . T sequence is 
longer in the present structure, the dimensions of the minor 
groove are quite similar in all isomorphous dodecamer struc- 
tures containing A and T residues, either continuous or al- 
ternating. An analysis of all complexes of the d(CGCAAAT- 
TTGCG) dodecamer with minor-groove-binders seems to in- 
dicate a widening of the groove upon drug-binding, when 
compared with the drug-free structure. This is not the case 
when the comparison is made with a redetermined native 
d(CGCAAATTTGCG) structure (Edwards et al., 1992). The 
latter was crystallized in the presence of the minor-groove- 
binder pentamide, although the drug was not found to be in 
the crystal. 
Hoechst 33258 is a molecule with three rigid planar 
groups. Because it is forced to follow the minor groove of 
the DNA double helix, there must be some torsion between 
the planar groups (phenol, benzimidazole 1 and 2) and be- 
tween benzimidazole 2 and the piperazine ring (Fig. 1). In 
all Hoechst 33258-DNA complexes the different structural 
groups of the drug are in different planes. The particular val- 
ues of the angles between these planes are not coincident 
although they fall inside a range 5-37". The differences re- 
flect the different positions of the drug which adapts to the 
irregular curve of the minor groove. 
